Present position of the hormonal replacement therapy;Současné postavení hormonální substituční terapie

Casopis Lekaru Ceskych

Volumn 143, Issue 7, 2004, Pages 447-452

  Fait, Tomáš ^a   Vokrouhlicka J ^a   Vrablik M ^a   Jenicek J ^b,c   Strnad, Pavel ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Centrum Klimaktericke Mediciny   (Czech Republic)

Author keywords

Climacteric syndrome; Hormone replacement therapy; Osteoporosis; Urogenital atrophy

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CALCIUM; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN DERIVATIVE; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PLACEBO; RALOXIFENE; SELECTIVE TISSUE ESTROGEN ACTIVITY REGULATOR; UNCLASSIFIED DRUG; VITAMIN D;

ATHEROSCLEROSIS; ATROPHY; BREAST CANCER; CANCER INCIDENCE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; OSTEOPOROSIS; REVIEW; SECONDARY PREVENTION; STROKE; THROMBOEMBOLISM; UROGENITAL TRACT DISEASE; BREAST TUMOR; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; ESTROGEN THERAPY; FEMALE; POSTMENOPAUSE OSTEOPOROSIS; RISK FACTOR;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; THROMBOEMBOLISM;

EID: 4043062190     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Jeníček, J.: Hormonální substituč ní terapie a klimakterium. Praha, Grada, 2001, 101 s.
2. Gordon, T., Kannel, W. B., Hjortland, M. C. et al.: Menopause and coronary heart disease. The Framingham study. Ann. Intern. Med., 1978, 89, s. 157-161.
3. Fait, T., Málková, J., Živný, J.: Vliv hormonální substituční terapie na kardiovaskulární systém. Čes. Gynek., 2002, 5, s. 285-293.
4. Gruchow, H. W., Anderson, A. J., Barboriah, J. J. et al.: Postmenopausal use of estrogen and occlusion of coronary arteries. Amer. Heart. J., 1988, 115, s. 954-963.
5. Henderson, B. E., Paganini-Hill, A., Ross, R. K.: Decreased mortality in user of ERT. Arch. Intern. Med., 1991, 151, s. 269-277.
6. Sullivan, J. M., van der Zwaag, R., Lemp, G. F. et al.: Postmenopausal estrogen use and coronary atherosclerosis. Ann. Intern. Med., 1988, 108, s. 358-363.
7. Walsh, B. W., Schiff, I., Rosner, B. et al.: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N. Engl. J. Med., 1991, 325, s. 1196-1204.
8. The Writing Group for the PEPI Trial: Effect of estrogen or estrogen/progestin regimens on heart disease factors in postmenopausal women. JAMA, 1995, 273, s. 199-208.
9. Haarbo, J., Marslew, U., Gotfredsen, A. et al.: Postmenopausal HRT prevents central distribution of body fat after menopause. Metabolism, 1991, 40, s. 1323-1326.
10. Magnes, R. R., Rosenfeld, C. R.: Local end systemic estradiol, effects on uterine and systemic vasodilatation. Am. J. Physiol., 1989, 256, s. 536-542.
11. Wouters, M. G., Moorrees, M. T., van den Mooren, M. J. et al.: Plasma homocystein and menopausal status. Eur. J. Clin. Invest., 1995, 24, s. 733-736.
12. Colditz, G. A., Willett, W. C., Stampfer, M. J. et al.: Menopause and the risk of coronary heart disease in women. NEJM, 1987, 316, s. 1105 až 1110.
13. Grodstein, F., Stampfer, M. J.: Selection bias and studies of HRT. European consensus development conference. Montreux, 1996, s. 151 až 155.
14. Grodstein, F., Meir, J., Stampfer, M. J. et al.: Postmenopauzal estrogen and progestin use and the risk of cardivascular disease. NEJM, 1996, 335, s. 453-461.
15. Schlipak, M. G., Angeja, B. D., Go, A. S. et al.: Hormone Therapy and in-Hospital Survival after Myocardial Infarction in Postmenoapusal Women. Circulation, 2001, 104, s. 2300-2304.
16. Bush, T. L., Barret-Connor, E., Cowan, L. D. et al.: Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation, 1987, 75, s. 1102-1109.
17. Hulley, S., Grady, D., Bush, M.: Randomised trial of estrogen plus progestin for secondary prevention of coronary heart desease in postmenopausal women. JAMA, 1998, 280, s. 605-613.
18. Grady, D., Herrington, D., Bittner, V.: Heart and estrogen/progestin replacement study follow-up (HERS II). Cardiovascular disease outcomes during 6-8 years of hormone therapy. JAMA, 2002, 288, s. 49-57.
19. Furberg, C. D., Vittinghoff, E., Davidson, M. et al.: Subgroup interactions in the heart and estrogen-progestin replacement study. Circulation, 2002, 105, s. 917-922.
20. Clarke, S. C., Kelleher, J., Lloyd-Jones, H. et al.: A study of hormone therapy in postmenopausal women with ischaemic heart desease. Br. J. Obst. Gyn., 2002, 109, s. 1056-1062.
21. Waters, D. D., Aldermann, L. A.: Effects of HRT and antioxidant vitamin suplements on coronary atherosklerosis in postmenopausal women. JAMA, 2002, 288, s. 2432-2439.
22. Angerer, S., Stork, S., Kothny, W.: Effect of postmenopausal hormone replacement on atherosclerosis in femoral arteries. Maturitas, 2002, 41, s. 51-60.
23. Writing Group for Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288, s. 321-333.
24. Notelovitz, M.: The clinical practice impact of the WHI: political vs biologic correctness. Maturitas, 2003, 44, s. 29-34.
25. Neves-E-Castro, M.: Menopause in crisis post-WHI? A view based on personal clinical experience. Hum. Reprod., 2003, 18, s. 2512-2518.
26. Pines, A.: Lessons from the WHI using HRT with regard to heart desease - the dream been broken? Harefuah, 2003, 142, s. 163-165.
27. Genazzani, A. R., Gambacciani, M.: A personal initiative for women's health: to chalange the Women's Health Initiative. Gynecol. Endocrinol, 2002, 16, s. 255-257.
28. Manson, J. E., Hsia, J., Johnson, K. C. et al.: Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med., 2003, 349, s. 523.
29. Hodis, H. N., Mack, W. J., Lobo, R. A. et al: Estrogen in the prevention of atherosclerosis. Ann. Int. Med., 2001, 135, s. 939-953.
30. Fait, T., Vrablík, M.: Vývoj názorů na vliv hormonální substituční terapie na riziko ischemické choroby srdeční. Prakt. Gynek., 2002, 10, s. 19-21.
31. Donát, J.: Hormonální substituční terapie. Hradec Králové, DoMeNa, 1999, 191 s.
32. Hoibraaten, E., Qvigstad, E., Amesen, H. et al.: Increased risk in recurrent venous tromboembolism during HRT - results of the randomized, double-blind, placebo-controlled estrogen in venous tromboembolism trial (EVTET). Tromb. Haemost., 2000, 84, s. 961-967.
33. Paganini-Hill, A., Ross, R. K., Henderson, B. E.: Postmenopausal estrogen treatment and stroke: a prospective study. Brit. Med. J., 1988, 297, s. 519-522.
34. Finucane, F. F., Madans, J. H., Bush, T. L. et al.: Decreased risk of stroke among postmenopausal hormone users. Arch. Intern. Med., 1993, 153, s. 73-79.
35. Viscoli, C. M., Brass, L. M., Keman, W. N. et al.: A clinical trial of ERT after ischemic stroke. A Engl. J. Med., 2001, 345, s. 1243.
36. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy. Lancet, 1997, 350, s. 1047 až 1059.
37. Millin Women Study Collaborators: Breast cancer and HRT in the Million Women Study. Lancet, 2003, 362, s. 419-427.
38. Fait, T.: Komentář - Speroff, L., Clarkson, T. B.: Je tibolon reálnou alternativou hormonální substituční terapie. Gyn. po promoci 5/2003, s. 27-29.
39. Speroff, L.: The million women study and breast cancer. Maturitas, 2003, 46, s. 1-16.
40. Berkvist, W. R., Adami, H. O., Persson, L. et al.: Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogenprogesterone replacement therapy. Am. J. Epidemiol., 1992, 130, s. 221-228.
41. Gapstur, S. M., Morrow, M., Sellers, T. A.: HRT and risk of breast cancer with favorable histology. Results of the Iowa Women's Health Study. JAMA, 1999, 281, s. 2140-2141.
42. Beral, V., Banks, E., Reeves, G.: Evidence from randomised trials on the long-term effects of HRT. Lancet, 2002, 360, s. 942-944.
43. Wells, G., Tugwell, S., Shea B. et al.: Meta-analysis of the efficacy of HRT in treating and preventing osteoporosis in postmenopausal women. Edocrine Rev., 2002, 23, s. 529-539.
44. Recker, R. R., Davies, K. M., Dowd R. M. et al.: The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. Ann. Intern. Med., 1999, 130, s. 897-904.
45. Ettinger, B., Genant, H. K., Steiger, S. et al.: Low-dose micronized 17-estradiol prevents bone loss in postmenopausal women. Amer. J. Obstet. Gynecol., 1992, 166, s. 479-488.
46. Notelovitz, M., Johnston, M., Smith, S. et al.: Metabolic and hormonal effects of 25-mg and 50-mg 17â-estradiol implants in surgically menopausal women. Obstet. Gynecol., 1987, 70, s. 749-754.
47. Broulík, P.: Osteoporóza. Praha, Maxdorf, 1999, 172 s.
48. Randell, K. M., Hokanen, R. J., Kroger, H. et al.: Does hormone-replacement therapy prevent fractures in early postmenopausal women? J. Bone Miner. Res., 2002, 17, s. 528-533.
49. Štěpán, J. J., Pospichal, J., Presl, J. et al.: Prospective trial of ossein-hydroxyapatite compound (OHC) in surgically induced postmenopausal women. Bone, 1989, 10, s. 179-185.
50. Rymer, J., Robinson, J., Fogelman, I.: Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric, 2002, 5, s. 309-326.
51. Kanis, J. A., Johnell, O., Black, D. M. et al.: Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation Trial. Bone, 2003, 33, s. 293-300.
52. Donát, J.: Kontroverzní "Doporučení SÚKL, týkající se bezpečnosti HRT" v rozporu se stanovisky NAMS a IMS. Klim. Medicina, 2003, 4, s. 4-13.
53. Col, N., Pauker, S. G.: The discrepancy between observational studies and randomized trials of menopausal HRT: did expectations shape experience? Ann. Intern. Med., 2003, 139, s. 923-929.
54. Genazzani, A. R., Gambacciani, M., van der Mooren, M. J. et al.: Critical comments. Maturitas, 2003, 44, s. 11-18.
55. Fait, T.: Individualizace hormonální substituč ní terapie. Postgraduální medicína 5/2003, s. 144-149.